zurück

Remdesivir (new indication: COVID-19; patients requiring supplemental oxygen; patients aged ≥ 4 weeks to < 12 years)

 

Subject:

  • Active Substance: Remdesivir
  • Name: Veklury®
  • Therapeutic area: Coronavirus disease 2019 (COVID-19)
  • Pharmaceutical company: Gilead Sciences GmbH

 

Time table:

  • Start: 15.10.2022
  • Publication of assessment: 16.01.2023
  • End of public hearing: 06.02.2023
  • Final decision by G-BA: beginning of April 2023

 

Comparative therapy:

  • Therapy at the physician's discretion